Inventor · disambiguated record
Kieron E. Wesson
Also filed as: WESSON KIERON · WESSON KIERON E
26 granted patents·8 pending applications·329 citations·filing 2003–2023
96Inventor score
Files withPTC THERAPEUTICS INC8EDISON PHARMACEUTICALS INC7BIOELECTRON TECH CORP4HINMAN ANDREW W3KOLESNIKOV ALEKSANDR2
Top patents by PatentIndex Score
34 records- 0198US7968746B24-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseasesEDISON PHARMACEUTICALS INC·Filed 2008·Granted Jun 28, 2011·46 cites·14 claims
- 0297US8575369B2Process for the production of alpha-tocotrienol and derivativesWESSON KIERON E·Filed 2012·Granted Nov 5, 2013·34 cites·28 claims
- 0397US8106223B2Process for the production of alpha-tocotrienol and derivativesWESSON KIERON E·Filed 2009·Granted Jan 31, 2012·46 cites·28 claims
- 0496US8519001B24-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseasesJANKOWSKI ORION D·Filed 2011·Granted Aug 27, 2013·30 cites·20 claims
- 0595US9169196B24-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseasesEDISON PHARMACEUTICALS INC·Filed 2013·Granted Oct 27, 2015·11 cites·24 claims
- 0695US8716527B22-substituted-p-quinone derivatives for treatment of oxidative stress diseasesHINMAN ANDREW W·Filed 2009·Granted May 6, 2014·35 cites·14 claims
- 0794US8716486B22-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseasesHINMAN ANDREW W·Filed 2009·Granted May 6, 2014·37 cites·31 claims
- 0891US9278085B2Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkersMILLER GUY M·Filed 2007·Granted Mar 8, 2016·19 cites·14 claims
- 0991US8299110B22-(2-hydroxybiphenyl-3-yl)-1H-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitorsKOLESNIKOV ALEKSANDR·Filed 2011·Granted Oct 30, 2012·8 cites·2 claims
- 1090US8952071B2(Het)aryl-p-quinone derivatives for treatment of mitochondrial diseasesHINMAN ANDREW W·Filed 2009·Granted Feb 10, 2015·18 cites·16 claims
- 1188US7479502B22-(2-hydroxybiphenyl-3-yl)-1H-benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitorsPHARMACYCLICS INC·Filed 2003·Granted Jan 20, 2009·15 cites·8 claims
- 1285US9486435B2(Het)aryl-p-quinone derivatives for treatment of mitochondrial diseasesEDISON PHARMACEUTICALS INC·Filed 2014·Granted Nov 8, 2016·7 cites·17 claims
- 1384US8778625B22-(2-hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitorsKOLESNIKOV ALEKSANDR·Filed 2012·Granted Jul 15, 2014·3 cites·2 claims
- 1483US9090576B22-substituted-p-quinone derivatives for treatment of oxidative stress diseasesEDISON PHARMACEUTICALS INC·Filed 2014·Granted Jul 28, 2015·3 cites·22 claims
- 1583US2022204469A1Process for the production of alpha-tocotrienol and derivativesPTC THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1682US10251847B2Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamideBIOELECTRON TECH CORP·Filed 2015·Granted Apr 9, 2019·3 cites·21 claims
- 1782US2023364029A1Polymorphic forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamidePTC THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1881US9932286B2Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkersBIOELECTRON TECH CORP·Filed 2015·Granted Apr 3, 2018·3 cites·8 claims
- 1981US9073873B22-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseasesEDISON PHARMACEUTICALS INC·Filed 2014·Granted Jul 7, 2015·4 cites·17 claims
- 2079US11840497B24-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseasesPTC THERAPEUTICS INC·Filed 2021·Granted Dec 12, 2023·0 cites·13 claims
- 2178US11938101B2Polymorphic forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamidePTC THERAPEUTICS INC·Filed 2022·Granted Mar 26, 2024·0 cites·13 claims
- 2276US11312697B2Process for the production of alpha-tocotrienol and derivativesPTC THERAPEUTICS INC·Filed 2018·Granted Apr 26, 2022·0 cites·22 claims
- 2376US8415328B2Factor VIIa inhibitorDICKMAN DANIEL A·Filed 2011·Granted Apr 9, 2013·4 cites·3 claims
- 2475US10189830B2Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disordersBIOELECTRON TECH CORP·Filed 2014·Granted Jan 29, 2019·3 cites·14 claims
- 2573US2022133648A1Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinonesPTC THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2672US2020360302A1Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinonesPTC THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2771US10968166B24-(P-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseasesPTC THERAPEUTICS INC·Filed 2018·Granted Apr 6, 2021·0 cites·9 claims
- 2868US9162986B22-(2-hydroxybiphenyl-3-yl)-1H-benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitorsPHARMACYCLICS LLC·Filed 2014·Granted Oct 20, 2015·0 cites·3 claims
- 2967US10167251B24-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseasesBIOELECTRON TECH CORP·Filed 2016·Granted Jan 1, 2019·0 cites·33 claims
- 3067US2014221674A1Process for the production of alpha-tocotrienol and derivativesEDISON PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 3166US9546132B24-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseasesEDISON PHARMACEUTICALS INC·Filed 2015·Granted Jan 17, 2017·0 cites·12 claims
- 3264US2010029706A1HYDROGENATED PYRIDO[4,3-b]INDOLES FOR THE TREATMENT OF OXIDATIVE STRESSEDISON PARMACEUTICALS INC A DE·Filed 2009·Application pending·0 cites
- 3363US2009054432A12-(2-Hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-Carboxamidine Derivatives as Factor VIIA InhibitorsPHARMACYLICS INC A DELAWARE CO·Filed 2008·Application pending·0 cites
- 3447US2008275250A1Factor Viia InhibitorPHARMACYCLICS INC·Filed 2005·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →